Sakar Healthcare Reports 38% Revenue Growth in Q1 FY27; PAT Surges 120% on Strong Oncology Business Momentum

What Happened ?

key details

Strong Financial Growth:

The company reported healthy growth across all major financial parameters.

• Revenue increased 38% YoY to ₹72.97 crore.
• Gross profit grew 61% to ₹38.39 crore.
• EBITDA increased 67% to ₹21.25 crore.
• PAT more than doubled, rising 120% to ₹10.28 crore.
• Operating margins improved significantly across all profitability metrics. 

Oncology Business Expansion:

Sakar continued strengthening its oncology manufacturing platform.

Key developments included:

• Executed more than 65 oncology product contracts.
• Over 50 commercial discussions currently underway.
• Continued expansion of global oncology partnerships.
• Strengthened long-term oncology manufacturing capabilities through API integration. 

Regulatory Progress:

The company achieved significant milestones across regulated markets.

• Shared 261 dossiers globally.
• 178 dossiers have already been submitted.
• 16 marketing authorisations received.
• Shared dossiers for 21 out of 32 developed oncology products.
• Secured 16 dossier approvals.
• Completed 26 EU marketing authorisation filings, including 15 owned filings.
• Additional approvals obtained through partners in Bulgaria and Bosnia, with filings progressing across the Czech Republic, Croatia and Portugal.

API Development:

The company continued strengthening backward integration.

Major achievements include:

• Developed 21 in-house APIs.
• 16 APIs received Written Confirmation.
• 8 APIs have been commercialised.
• 2 APIs obtained CEP approval.
• 5 CEP applications remain under regulatory review.

Technology Transfer & Global Partnerships:

Sakar expanded collaborations with leading pharmaceutical companies.

Highlights include:

• 33 technology transfer projects currently underway.
• Partnerships with Accord-Intas, Torrent, Emcure, Glenmark and Zydus.
• Seven site variation approvals received during the quarter.
• Projects span regulated markets including the UK and the European Union. 

International Expansion:

The company continued expanding its global regulatory footprint.

Important developments include:

• Submitted 33 site variation applications covering 18 cytotoxic molecules across Europe and the UK.
• Seven site variations have already been approved.
• Continued strengthening presence across more than 60 countries.
• Regulatory approvals continue supporting future commercial launches and export growth. 

Management Commentary:

Managing Director Sanjay Shah stated that the company’s revenue and profitability continue to grow steadily, supported by expanding oncology capabilities, regulatory progress and increasing commercial engagement.

Management expects ongoing regulatory approvals, commercial launches, improving capacity utilisation and higher oncology volumes to drive sustainable long-term growth while strengthening operating leverage. 

Note:

• Q1 FY27 reflects continued execution of Sakar Healthcare’s long-term oncology strategy.
• The combination of robust financial performance, expanding API integration, increasing regulatory approvals and growing international commercialisation strengthens the company’s position in regulated pharmaceutical markets and provides visibility for future growth. 

Risk Analysis

Summary:

• While business momentum remains strong, future growth will depend on timely regulatory approvals, successful commercialisation of oncology products and continued expansion across export markets.

Key Risks:

• Commercialisation depends on regulatory approvals in international markets.
• Export growth remains sensitive to regulatory timelines.
• Oncology business execution requires successful technology transfers.
• Capacity utilisation improvements depend on higher commercial volumes.
• Pharmaceutical manufacturing remains subject to stringent regulatory compliance. 

Worst Case:

• If regulatory approvals are delayed or commercial launches progress slower than expected, the company may experience slower revenue growth and lower operating leverage despite maintaining a strong product pipeline.

Risk Level: Medium

Company Commentary

• Revenue increased 38%, while PAT surged 120% during Q1 FY27.
• Oncology business continued expanding through new commercial contracts and global partnerships.
• Regulatory progress accelerated with 261 dossiers shared, 16 marketing authorisations and 26 EU filings.
• API integration continued strengthening with 21 in-house APIs and multiple regulatory certifications.
• Management remains confident that increasing oncology commercialisation, export growth and improving operating leverage will support sustainable long-term value creation.